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agonistic effects. The reaction products were separated by SDS-
PAGE, followed by Coomassie Blue or silver staining. Treatment
of cartilage explants with HtrA1: Human osteoarthritic cartilage
explants were treated with recombinant HtrA1, with or without
CPII. Conditioned media were assayed for sGAG release by
DMMB. Proteoglycans in the media were precipitated using 1%
cetylpyridinium chloride and subjected to SDS-PAGE followed by
Coomassie Blue or silver staining.
Results: The cartilage proteoglycan aggrecan was identiﬁed
as one of the potential substrates of HtrA1 in the mass
spectrometry-based “degradomics” analysis. Incubation of re-
combinant aggrecan G1-IGD-G2 and IGD constructs with wild-
type HtrA1, but not mutant HtrA1, resulted in distinct cleavage
of these substrates. HtrA1 activity was further enhanced by the
peptide agonist CPII, and inhibited by the HtrA inhibitor Ucf-101.
In addition, recombinant HtrA1 cleaved native human aggrecan in
the presence of the CPII peptide agonist. Treatment of cartilage
explants with recombinant HtrA1 signiﬁcantly increased (p<0.05)
the amount of sGAG released compared to control. Further, the
addition of CPII signiﬁcantly increased (p<0.05) the amount of
sGAG release compared to treatment with HtrA1 alone.
Conclusions: Our data suggest that the collagen type II C-
propeptide may induce proteoglycan catabolism by stimulating
the protease activity of HtrA1. Elevated levels of collagen type
II C-propeptide have been detected in osteoarthritic human ar-
ticular cartilage, due to increased collagen synthesis. Excessive
HtrA1 protease activity in OA cartilage may represent another
contributing factor in OA disease progression.
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Purpose: To evaluate the contribution of visfatin, an adipose
tissue-derived hormone, to the pathophysiology of osteoarthritis
(OA) by examining its role in prostaglandin E2 (PGE2) synthe-
sis and matrix degradation. In an inﬂammatory context, PGE2
synthesis is catalysed by cyclooxygenase type 2 (COX-2) and mi-
crosomal prostaglandin E synthase type 1 (mPGES-1), whereas
NAD+-dependent 15-hydroxy prostaglandin dehydrogenase (15-
PGDH) degrades PGE2.
Methods: The synthesis of visfatin by human chondrocytes
from OA patients, with and without stimulation with interleukin-
1β (IL-1β- 10 ng/ml), was assessed by real-time RT-PCR and
immunoblotting. The effects of visfatin (1 to 10µg/ml) on mPGES-
1, 15-PGDH, PGE2, MMP-3 and MMP-13 expressions by human
OA chondrocytes and by primary mouse articular chondrocytes
were examined by quantitative RT-PCR, immunoblotting and
ELISA. A siRNA strategy was used to assess the inﬂuence
of visfatin on the IL-1β induced release of PGE2. Finally, the
role of IGF-1R in visfatin signalling was studied using primary
chondrocytes from IGF-1R knockout mice (IGF-1R-/-).
Results: (1) Visfatin was constitutively expressed by cultured
human OA chondrocytes. Its expression increased 6-fold in re-
sponse to 10 ng/ml IL-1β (p<0.05).
(2) Visfatin at 1 to 5 µg/ml triggered MMP-3 and MMP-13
mRNA expression (up to 6-fold, p<0.01) by primary mouse
articular chondrocytes. Stimulation with 5 µg/ml visfatin led to a
release of 572 ± 280 ng/ml MMP-3 protein (p<0.05). Visfatin
also induced i) PGE2 release (controls 47 ± 8 versus 141 ± 10
pg/ml when treated with 10 µg/ml visfatin, p<0.05), ii increased
expression of the mPGES-1 (14-fold increase, p<0.01) and iii) a
90% decrease (p<0.05) of the 15-PGDH. Interestingly, 1 ng/ml
IL-1β plus visfatin (1, 2.5 or 5 µg/ml for 24 hours) had additive
effects on PGE2 release (19-fold, 31-fold and 35-fold compared
to IL-β, p<0.05; [1 ng/ml IL-β released 1506 ± 67 pg/ml]).
Moreover, IL-1β dramatically decreased 15-PGDH expression by
95% (p<0.001).
(3) Blocking visfatin expression by siRNA inhibited IL-1β-induced
PGE2 release: triggered the release of (1430 ± 467 pg/ml in
presence of IL-1β (10ng/ml) versus 985 ± 292 pg/ml in presence
of IL-1β + siRNA visfatin, -35%, p<0.01) probably due to a 40%
inhibition of mPGES-1 expression (p<0.01). (4) Visfatin is known
to bind to, and to activate insulin receptor (IR). However, IR is not
considered to be usually present on chondrocytes. We therefore
tested the implication of IGF-1R, a close homologue to IR, in
visfatin signalling. When stimulated with 5 µg/ml visfatin, IGF-
1R-/- chondrocytes unexpectedly exhibited higher PGE2 release
than IGF1R+/+ controls (228 ± 4 compared to 86 ± 29 pg/ml,
p<0.05) which rules out the direct implication of IGF-1R in visfatin
action.
Conclusions: Visfatin triggers the synthesis and the release of
MMP-3 and MMP-13 and induces PGE2 synthesis resulting from
an increase of mPGES-1 and a decrease of 15-PGDH expression
in chondrocytes. We therefore consider that visfatin is a novel
and a potential critical target for OA. In vivo experiments are now
needed to test this hypothesis.
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Purpose: Previous studies (Arthritis Rheum 52:3110-24) showed
that DNA de-methylation at speciﬁc CpG sites in the promoters
was associated with the abnormal synthesis of matrix-degrading
enzymes in human osteoarthritis. However, it is not known
whether DNA de-methylation actually causes the abnormal ex-
pression of the proteases. To demonstrate possible cause-effect
relationships and to study the mechanisms involved in the loss of
DNA methylation requires an in vitro system in which experimen-
tally induced gene induction is correlated with de-methylation at
speciﬁc CpG sites.
Methods: Since monolayer cultures of articular chondrocytes
are an established model to study the induction of the typical
OA proteases by inﬂammatory cytokines, we used this sys-
tem. Healthy chondrocytes were harvested from human femoral
head cartilage after hemi-arthroplasty following a fracture of the
neck of femur. The chondrocytes from each patient were di-
vided into ﬁve groups: non-culture; control culture; culture with
the de-methylating agent 5-aza-deoxycytidine (5-aza-dC) or the
inﬂammatory cytokines IL-1β or TNF-α/oncostatin M. At conﬂu-
ency (4-5 weeks), total RNA and genomic DNA were extracted
simultaneously. Relative mRNA expression was quantiﬁed by
SybrGreen-based real-time PCR and a method for quantifying
the percent of cells with DNA methylation at one speciﬁc CpG
site was developed (Epigenetics 2: 86-95). ELISA was used to
analyze IL-1β in the culture.
Results: Initial non-quantitative experiments conﬁrmed IL-1β -
induced expression of MMP-3 and MMP-13 and also demon-
strated induction of IL-1β by itself, which correlated with loss of
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DNA methylation in the IL-1β promoter in 3/5 patients. Further
work concentrated on this gene. Bisulﬁte modiﬁcation suggested
that the CpG sites at -290bp and - 247bp were important for
the epigenetic regulation of IL-1β, and the site at -290bp was
selected for quantiﬁcation of DNA methylation. We then deter-
mined which experimental conditions resulted in the greatest
loss of DNA methylation and whether this paralleled the in-
crease in mRNA expression. Culture with the de-methylating
factor 5-aza-dC halved DNA methylation, which resulted in 4-
8 fold increases in IL-1β expression compared with cultured
controls. This demonstrated that DNA de-methylation per se in-
creased gene expression. However, this was not the only factor
involved, since far greater effects were seen with the inﬂamma-
tory cytokines: IL-1β reduced methylation to ∼15%, cresulting in
50-100 fold increases in gene expression. The greatest effect
was seen with TNF-α/OSM, which abolished DNA methylation
almost completely and caused IL-1β expression to increase 500-
1000 fold. The cytokine-induced expression was translated into
protein. Unlike IL-1β, TNF-α expression was not susceptible to
auto-induction or epigenetic control.
Conclusions: A system has been developed in which loss of
DNA methylation in combination with 100-1000 fold increases in
gene expression can be induced experimentally - a crucial pre-
requisite for mechanistic studies. Moreover, we demonstrated for
the ﬁrst time that inﬂammatory cytokines can cause loss of DNA
methylation in addition to all other known effects, and that IL-1β
(but not TNF-α) induces its own expression.
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Purpose: Our previous work revealed differential roles for the
NF-κB activating kinases in controlling the progression towards
terminal differentiation of primary osteoarthritic chondrocytes.
Here we elaborate some of the multiple steps whereby IKKα
controls the terminal chondrogenic differentiation program.
Methods: Primary chondrocytes were derived from 15 Os-
teoarthritis (OA) patients undergoing joint arthroplasty. IKKα or
IKKβ shRNAs were stably expressed by pSuper retroviral trans-
duction of IKKα or IKKβ speciﬁc shOligos followed by selection
of puromycin resistant cells and KD efﬁciencies were veriﬁed by
immunoblotting. High density monolayer and micromass cultures
under mineralizing conditions were selected to investigate the
mechanisms whereby the IKKs control chondrocyte terminal dif-
ferentiation. Runx2 was evaluated by both REAL TIME PCR in 1
week old micromasses and by immunohistochemistry in 3 week
old micromasses and Sox9 expression in high density monolayer
cultures by immunoblotting. The effects of IKKα KD on type 2
collagen accumulation at the transcriptional or post-translational
levels were investigated in micromasses. ECM remodelling was
directly evaluated by staining for neoepitopes (Col2 3/4 C and
DIPEN and NITEGE). Moreover, IKKα expression was rescued
in IKKα KD chondrocytes with either a wild type or kinase-dead
IKKα(K44M) mutant to explore the connection between IKKα’s
effects on chondrogenesis and the NF-κB pathway.
Results: IKK KDs were at least 80% and generally greater than
90%. Both IKK KD were found associated with increased Col2
mRNA expression and also resulted in defective ECM remod-
elling as shown by IHC detection of neoepitopes. Silencing IKKβ
markedly increased sGAG accumulation, in conjunction with in-
creased Sox9 expression. However, IKKα ablation markedly en-
hanced collagen 2 deposition independently of Sox9 but instead
in association with a strong remodelling block in conjunction with
Runx2 suppression. In addition ablation of either IKKα or IKKβ
also inhibited Collagen X deposition thus providing additional
evidence, along with blocks in calcium deposition, that each IKK
(albeit via different mechanisms) is of central importance for
progression towards terminal differentiation.
Conclusions: We have uncovered an unexpected, pivotal role
for IKKα in the terminal chondrogenesis of primary osteoarthritic
human chondrocytes. IKKα controls the transition to the hyper-
trophic phase at multiple levels, while IKKβ appears to mimick
the effects of canonical NF-κB activation. Preliminary indications
of an IKKα rescue experiment suggest that its more profound ef-
fects could be independent of the NF-κB pathway. In conjunction
with the healthier status of IKKα KD chondrocytes, with respect
to their extensive ECM and high viability, our results support
the view that IKKα could be a novel therapeutic target for Os-
teoarthritis with its ablation causing a profound blockage towards
terminal differentiation.
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Purpose: While investigating the effects of sharp injury upon
inﬂammatory signalling pathways in articular cartilage, we found
that synovial ﬂuid strongly activated MAP kinases in cartilage
explants adapted to culture. We set out to identify the activator
and investigate its effects on chondrocyte function.
Methods: Cartilage from porcine metacarpophalangeal joints
was cultured in serum-free medium for 24h before treatment with
porcine synovial ﬂuid. Tissue extracts were analysed for MAPK
(ERK, p38 and JNK) and ATF-2 (a preferred JNK substrate)
activation by phospho-Western blotting. Culture medium sam-
ples were analysed for the presence of aggrecanase-generated
aggrecan fragments by using antibodies against the aggrecan
ARGS neoepitope. Porcine synovial ﬂuid was subjected to se-
quential chromatography (Resource Q, Resource S and Blue
Sepharose) and the MAPK activator was identiﬁed by mass-
spectrometry.
Results: The porcine synovial ﬂuid activator was identiﬁed as
apolipoprotein A-1 (APOA-1) the major component of high den-
sity lipoprotein (HDL) in tissue ﬂuids. Porcine APOA-1 puriﬁed
from synovial ﬂuid and commercially available human APOA-1
activated MAPKs and also induced aggrecan breakdown in cul-
tured cartilage. APOA-1 induced mRNA of ADAMTS-4 and -5
and MMP-13. APOA-1 differed from typical inﬂammatory medi-
ators that cause cartilage catabolism (IL-1, TNF, LPS), in that it
did not induce cyclooxygenase-2 (COX-2), a typical inﬂammatory
response gene.
Conclusions: APOA-1 in synovial ﬂuid causes MAPK activa-
tion and induces aggrecanases in cartilage. It appears to cause
a matrix-resorbing response without inducing inﬂammatory re-
sponse genes. APOA-1 (apparent Mr ∼120kD) may normally be
excluded from the cartilage matrix but is perhaps able to access
